Adjuvant Durvalumab and the Future of Early-Stage NSCLC

from Journal of Clinical Oncology (JCO) Podcast

Guest Dr. Glenwood Goss and host Dr. Davide Soldato discuss JCO article, "Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer" and the implications of minimal residual disease, results regarding the efficacy of immunotherapy in the adjuvant setting, and the evolving strategies for patient care in lung cancer treatment. LINK TO FULL TRANSCRIPT

Episode metadata supplied by the publisher feed · Published May 14, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Adjuvant Durvalumab and the Future of Early-Stage NSCLC

0:00 20:04

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Journal of Clinical Oncology (JCO) Podcast?

This episode is 20 minutes long.

When was this Journal of Clinical Oncology (JCO) Podcast episode published?

This episode was published on May 14, 2026.

Can I download this Journal of Clinical Oncology (JCO) Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!